Guangzhou Welman Pharmaceutical

Guangzhou Welman Pharmaceutical is a prominent Chinese pharmaceutical firm focused on the development and production of anti-infective, cardiovascular, and metabolic medications. Established in 1995, the company gained significant recognition for its expertise in beta-lactamase inhibitor combinations, notably being the first to launch Cefoperazone Sodium and Sulbactam Sodium in China. In 2022, the company was acquired by Hunan Jiudian Pharmaceutical, integrating its robust manufacturing capabilities and established product portfolio into the larger group. Welman operates high-standard GMP facilities in Guangzhou, producing a variety of injectable and oral therapies. Its research efforts continue to target multi-drug resistant bacterial infections and chronic diseases. The company remains a vital player in the Chinese domestic market for essential hospital-use antibiotics.